← stocks-llm Find companies like INDV →

INDIVIOR PHARMACEUTICALS INC (INDV)

Health Care · Specialty pharmaceuticals - addiction and pain management · NASDAQ

Indivior is a specialty pharmaceutical company focused on treating addiction and related disorders, with a primary product portfolio anchored by SUBLOCADE, a long-acting buprenorphine injection.

What INDIVIOR PHARMACEUTICALS INC does

Indivior Pharmaceuticals is a specialty pharmaceutical company that manufactures and distributes medications addressing addiction, pain, and other indications. The company relies heavily on SUBLOCADE, a long-acting buprenorphine injection, for a significant portion of its revenues. Indivior operates under stringent regulatory requirements as a manufacturer and distributor of controlled substances, and relies on third-party payors and government reimbursement programs for revenue generation. The company faces competition in the pharmaceutical industry while maintaining manufacturing facilities and managing complex supply chains.

Themes: ["Addiction and substance use disorder treatment","Opioid use disorder medications","Controlled substances manufacturing","Specialty pharmaceuticals"]

Fundamentals

Ask why INDV looks like this →

Key risks (from latest filing)

["Heavy revenue concentration in SUBLOCADE; slower-than-expected revenue growth or market adoption could materially harm business and profitability.","Leveraged balance sheet with long-term debt obligations; reduction in revenues may adversely affect liquidity and profitability.","Subject to stringent manufacturing practices, regulatory inspection, product liability claims, and risks related to distribution of controlled substances."]

See INDV's biggest risks from its latest 10-Q →

Competitors & peers

Not quite? Describe exactly what you want →

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.